文献速递妇科肿瘤

分子分型可预测早期子宫内膜样子宫内膜癌放疗反应:随机PORTEC-1与PORTEC-2试验

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
PubMed 文献 · J Clin Oncol · 2023-07-24

研究利用PORTEC-1(714例)和PORTEC-2(427例)随机试验数据,对880例早期子宫内膜样子宫内膜癌进行分子分型,比较不同分子亚型对外照射放疗、阴道近距离放疗或无辅助治疗的区域复发控制效果。中位随访11.3年,结果显示POLEmut型无区域复发,MMRd型各治疗组无差异,p53abn型外照射优于阴道近距离放疗和无辅助治疗,NSMP型阴道近距离放疗与外照射等效且优于无辅助治疗。

要点

  • POLEmut型子宫内膜癌未观察到区域复发,省略放疗似乎是安全的。
  • p53abn型子宫内膜癌外照射(96.9%)优于阴道近距离放疗(64.3%)和无辅助治疗(72.2%;P = .048)。
  • NSMP型子宫内膜癌阴道近距离放疗(96.2%)与外照射(98.3%)等效,均优于无辅助治疗(87.7%;P < .0001)。

核心结论

  • 子宫内膜癌分子分型可预测I期子宫内膜样子宫内膜癌对放疗的反应,并可能指导辅助治疗决策。
  • POLEmut型子宫内膜癌省略放疗似乎是安全的。
  • MMRd型子宫内膜癌放疗获益似乎有限。
  • p53abn型子宫内膜癌外照射的区域无复发生存显著优于阴道近距离放疗或无辅助治疗。
  • NSMP型子宫内膜癌阴道近距离放疗是治疗选择,因其与外照射等效且区域肿瘤控制显著优于无辅助治疗。

研究设计与样本

  • 研究使用随机PORTEC-1试验(n = 714)比较盆腔外照射与无辅助治疗在早期中危子宫内膜癌中的效果。
  • 研究使用随机PORTEC-2试验(n = 427)比较阴道近距离放疗与外照射在早期高危中危子宫内膜癌中的效果。
  • 共纳入880例完成分子分型的子宫内膜癌,其中PORTEC-1组484例,PORTEC-2组396例。
  • 大多数为FIGO-2009 I期子宫内膜样子宫内膜癌(97.2%),中位随访11.3年。

主要发现

  • POLEmut型子宫内膜癌未观察到区域复发。
  • MMRd型子宫内膜癌外照射后区域无复发生存94.2%,阴道近距离放疗后94.2%,无辅助治疗后90.3%(P = .74),组间相似。
  • p53abn型子宫内膜癌外照射后区域无复发生存96.9%,阴道近距离放疗后64.3%,无辅助治疗后72.2%(P = .048),外照射有实质性获益。
  • NSMP型子宫内膜癌外照射后区域无复发生存98.3%,阴道近距离放疗后96.2%,无辅助治疗后87.7%(P < .0001),两种放疗均优于无辅助治疗。

关键数值与推荐

  • MMRd型子宫内膜癌:外照射94.2% vs 阴道近距离放疗94.2% vs 无辅助治疗90.3%(P = .74),区域无复发生存相似。
  • p53abn型子宫内膜癌:外照射96.9% vs 阴道近距离放疗64.3% vs 无辅助治疗72.2%(P = .048),外照射优于其他两组。
  • NSMP型子宫内膜癌:外照射98.3% vs 阴道近距离放疗96.2% vs 无辅助治疗87.7%(P < .0001),放疗组优于无辅助治疗。
  • POLEmut型子宫内膜癌:未观察到区域复发。

临床怎么用

  • 分子分型可能指导早期子宫内膜样子宫内膜癌的辅助治疗决策。
  • POLEmut型子宫内膜癌省略放疗似乎是安全的。
  • p53abn型子宫内膜癌外照射的区域无复发生存显著优于阴道近距离放疗或无辅助治疗。
  • NSMP型子宫内膜癌阴道近距离放疗是治疗选择,因其与外照射等效且区域肿瘤控制显著优于无辅助治疗。
  • MMRd型子宫内膜癌放疗获益似乎有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The molecular classification of endometrial cancer (EC) has proven to have prognostic value and is predictive of response to adjuvant chemotherapy. Here, we investigate its predictive value for response to external beam radiotherapy (EBRT) and vaginal brachytherapy (VBT) in early-stage endometrioid EC (EEC). METHODS: Data of the randomized PORTEC-1 trial (n = 714) comparing pelvic EBRT with no adjuvant therapy in early-stage intermediate-risk EC and the PORTEC-2 trial (n = 427) comparing VBT with EBRT in early-stage high-intermediate-risk EC were used. Locoregional (including vaginal and pelvic) recurrence-free survival was compared between treatment groups across the four molecular classes using Kaplan-Meier's methodology and log-rank tests. RESULTS: A total of 880 molecularly classified ECs, 484 from PORTEC-1 and 396 from PORTEC-2, were included. The majority were FIGO-2009 stage I EEC (97.2%). The median follow-up was 11.3 years. No locoregional recurrences were observed in EC with a pathogenic mutation of DNA polymerase-ε (POLEmut EC). In mismatch repair-deficient (MMRd) EC, locoregional recurrence-free survival was similar after EBRT (94.2%), VBT (94.2%), and no adjuvant therapy (90.3%; P = .74). In EC with a p53 abnormality (p53abn EC), EBRT (96.9%) had a substantial benefit over VBT (64.3%) and no adjuvant therapy (72.2%; P = .048). In EC with no specific molecular profile (NSMP EC), both EBRT (98.3%) and VBT (96.2%) yielded better locoregional control than no adjuvant therapy (87.7%; P < .0001). CONCLUSION: The molecular classification of EC predicts response to radiotherapy in stage I EEC and may guide adjuvant treatment decisions. Omitting radiotherapy seems to be safe in POLEmut EC. The benefit of radiotherapy seems to be limited in MMRd EC. EBRT yields a significantly better locoregional recurrence-free survival than VBT or no adjuvant therapy in p53abn EC. VBT is the treatment of choice for NSMP EC as it is as effective as EBRT and significantly better than no adjuvant therapy for locoregional tumor control.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Horeweg N, Nout RA, Jürgenliemk-Schulz IM, et al. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer. J Clin Oncol. 2023. PMID: 37487144. doi:10.1200/JCO.23.00062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。